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In short-term studies, hormonal contraceptives (HC) have been suggested to induce
a rise in blood pressure (BP) and urinary albumin excretion (UAE), while the effect
of HC in renal function (GFR) is still under debate. Data on long-term and withdrawal
effects of HC use on these outcomes are, however, not available. We therefore studied




We used data from the PREVEND Study, a prospective cohort of subjects aged 28–




45 years with complete clinical and pharmacy
data on baseline and follow-up screening (4 years later). Multivariate regression






































BP increased among starters and fell in stoppers. These changes compared with
never-users were statistically significant, even after adjustment for relevant variables.



















 0.001) and did not change in
stoppers. The effects of stopping HC on UAE and GFR were significantly different











The start of HC was independently associated with worsening of BP, UAE and GFR,
while stopping HC use resulted in an improvement. These data suggest that long-
term HC use (aged 28–45 years) may be deleterious from the cardiovascular and




Hormonal contraceptives (HC) have been used for more
than three decades. Much attention has been drawn to
the thromboembolic and cardiovascular adverse events
associated with these agents. It has been generally
acknowledged since 1978 [1] that HC may increase
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blood pressure (BP). However, the activation of the
renin–angiotensisn system (RAS), recently suggested to
play a role in this mechanism of HC in elevated BP, is
still a matter of debate [2–5]. Although the association
between the use of HC and BP elevation has been
repeatedly demonstrated [5–7], few studies have shown
the beneficial effect on BP of cessation of HC [8, 9].
Epidemiological and pathophysiological data on HC
use and the renal outcome, e.g. albuminuria and renal
function, are limited. Interestingly, some studies have
recently described an association between the use of HC
and albuminuria [3, 5, 10]. Higher levels of albuminuria
are considered an early marker of vascular endothelial
damage [11, 12] and are related to an increased risk of
progressive renal failure and excess cardiovascular mor-
bidity and mortality [12–17]. The mechanism of the
effect of HC on urinary albumin excretion (UAE) is still
unknown, although there are studies showing that it may
be related to a systemic haemodynamic effect, i.e. an
increase in BP [1, 9, 18] or a specific renal effect [4, 19].
There is currently no evidence to suggest that HC use
predisposes women to renal disease. However, studies
on the association between HC and renal outcome have
so far been conducted in hypertensive [5] or diabetic
populations [3]. In the general population data are
scarce. Two studies have proposed that the use of HC
may be associated with an increased risk of microalbu-
minuria, independent of BP [5, 10]. The subjects
included in our previous cross-sectional study [10] have
now been followed for more than 4 years. Participants
have been screened for a second time and their drug use
has been monitored. We now present a prospective,
observational study, performed in this cohort of women,
investigating whether the long-term use of HC has an





Study design and population
 
This study is part of the PREVEND (Prevention of
REnal and Vascular ENd-stage Disease) study, an ongo-
ing, prospective study designed to investigate the impact
of UAE on renal and cardiovascular disease progression
in the general population. The formation of this cohort
study has been previously described in detail [10, 20].
Briefly, in 1997 a cohort of subjects aged 28–75 years
enriched for an elevated UAE was drawn from the pop-
ulation of the city of Groningen. Overall 8592 subjects
gave written informed consent and were included in
1997 in the observational cohort for extensive baseline
screening (baseline screening). The 8592 subjects, of
whom 95% were caucasians, were followed up for car-
diovascular and renal morbidity and mortality details
since the time of their baseline screening. They were
invited for a second screening after a mean follow-up
period of 4.2 years (range 2.8–6.1). By then 246 sub-
jects had died, 130 were lost to follow-up and 1322
declined participation, leaving 6894 subjects who com-
pleted the second screening. Of these 6894 subjects,





















 1880) and those for whom no
complete information on drug use during the follow-up








 1129). Thus, 751
subjects were available for further analysis. The changes
in BP, UAE and GFR from baseline compared with the





The methodology used in the PREVEND cohort study
has been described previously [10, 20]. The screening
examinations included two visits to an outpatient clinic,
the first visit including an interview on demographics,
medical history and smoking habits. During a physical
examination, weight, height and BP were measured.
Body weight was measured to the nearest 0.5 kg, using
a balance scale (seca Vogel & Halke GmbH & Co.,
Hamburg, Germany) after removal of shoes and heavy
clothing. Height was measured to the nearest 0.5 cm
using a statiometer measuring board with right angle.
Body mass index (BMI) was calculated as weight (kg)




). In the supine position,
BP in the right arm was measured on two visits, every
minute for 10 min using an automatic blood pressure
monitoring device (Dinamap XL Model 9300; Johnson-
Johnson Medical Inc., Tampa, FL, USA). Systolic BP
(SBP) and diastolic BP (DBP) were calculated as the
mean of the last two measurements at both visits. Fast-
ing blood samples were drawn for direct measurement
of total cholesterol, glucose and serum creatinine. Urine
was also collected for 2 days for measurement of UAE.
Plasma glucose, serum cholesterol and serum and
urinary creatinine were recorded based on the findings
of an automated dry chemistry analyser system (Kodak
Etachem; Eastmen Kodak, Rochester, NY, USA).
Urinary albumin concentration was determined by
















2.6%, respectively (Dade Behring Diagnostic,
Marburg, Germany). UAE is given as the mean of the













estimated using the Modification of Diet in Renal Dis-






















 (0.742 if female) [21].
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Information on drug use
 
Information on drug use was obtained from the InterAc-
tion Database (IADB), containing pharmacy-dispensing
data from community pharmacies in the city of Gronin-
gen. Dutch patients usually register at a single commu-
nity pharmacy, which can therefore provide an almost
complete listing of subjects’ prescribed drugs [22].
Pharmacy data contain, among others, information on
the name of the drug dispensed, Anatomical Therapeu-
tical Chemical (ATC) classification, date of prescription
and number of days the drug was prescribed and the
number of defined daily doses (DDDs) based on the
World Health Organization definition [23]. The use of
over-the-counter (OTC) drugs and in-hospital prescrip-
tions were not included. Information on drug use was
collected from at least 1 year prior to the date of the first




HC were defined as preparations containing ethinyl
estradiol and/or a progestin, either oral, injection or sub-
cutaneus implant. The intrauterine device (IUD) and
progestagen-only oral preparations (mini-pill contains
low potency progesteron) are not considered HC in this
study.
A subject was defined as using HC at the first screening
if she had used at least one prescription of the drug in
the year prior to the first screening. Women who had
used HC at the first screening, but stopped its use more









 117) and those who continued to use
it until the second screening [with a mean prescribed













 183) (the PDD was
calculated from the total amount of DDDs divided by
the number of days of exposure). The women who did
not use HC at the first screening but started to use it at









 73). Women who had used the hormone









 92) were not taken into account in this
study. Women who had never used HC in the entire









We similarly recorded the use of antihypertensive med-
ication, divided into agents interfering in the RAS, such
as ACE inhibitors or angiotensin II receptor blockers,
and other antihypertensives. The use of lipid-lowering
and glucose-lowering drugs was also registered.
We also studied subgroups of oral HC users according
to their progestin classified as second generation
(levonorgestrel, lynestrel and norethindrone) or third
generation (desogestrel, gestodene and norgestimate)
[24]. Subjects who received HC of only one generation
during the study period were included in the subgroup
analyses for the type of generation of HC. Subjects who
switched from one generation of HC to another were





Baseline characteristics are reported as mean and SD for
continuous variables and as percentage for categorical
variables. Because of its skewed distribution, logarith-
mic transformation of UAE was applied for further anal-
yses and reported values are transformed back to the
original scale (geometric means). Differences in popu-
lation characteristics at baseline between the various
groups under investigation were tested for continuous




-test for nonpaired data and for







We compared the percentage change in BP, UAE and
GFR between the first and second screenings for each









 was applied to test for changes in
blood pressure, UAE and GFR between groups with
never-users as reference. Multivariate linear regression
models were built to adjust the baseline parameters that
are known to influences changes in BP, UAE and GFR
such as age, SBP and DBP, BMI, cholesterol, glucose,
UAE and GFR. Similar analyses were performed to
study the association between the various generations of
HC and outcome. All calculations were performed with














Of the 751 women, 342 used HC at the time of the first
screening, while 409 women did not. Among the 342
women who used HC at baseline, 117 (34.2%) stopped
using the drug before the second screening (stoppers),
whereas 183 (53.5%) were still using it at the time of





of DDD (intermediate). Of the 409 subjects who did not
use HC at the baseline examination, 73 (17.8%) started
use of HC before the second screening (starters),
whereas 286 (69.9%) never used HC during the entire
follow-up period (never-users) and 50 used HC only for
a short period in between the two screenings (interme-








 92) were not included in
further analysis.
The characteristics of these subjects at baseline
according to their HC use at second screening are pre-
sented in Table 1. Women who never used HC were
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older and had a lower SBP and higher GFR compared
with those who used or had used HC. Other factors such
as DBP, plasma cholesterol, glucose, smoking status,
previous myocardial infarction, use of lipid- or BP-
lowering drugs and antidiabetics were not significantly
different between groups.
The effect of HC on SBP, DBP, UAE and GFR is
shown in Table 2. The start of HC was associated with
a rise in SBP and DBP, while SBP and DBP fell in
stoppers. The percentage change in BP among starters
and stoppers was statistically different from the change
in the never-users for both SBP and DBP, also after
adjustement for relevant variables.
A similar pattern is also found for UAE. Compared
with the first screening, UAE at second screening













 0.081) in those who never used HC,
although the difference between these two groups did







 0.201). In contrast, stopping HC use









This decrease was significantly different compared with





















 0.002), but also fell in






 0.001), while GFR in
stoppers did not change significantly. The fall in GFR
was greatest in those who started HC compared with
never-users and was smallest in those who stopped HC.











adjustment for other variables.
When studying the second- and third-generation
contraceptives separately (Table 3), starting a third-
generation HC resulted in an increase in SBP and DBP
compared with never-users. This was not the case









the other hand, subjects who stopped a second-genera-
tion HC showed a lowering of SBP, while stoppers of a
third-generation HC showed no difference in BP change
compared with never-users. Starting use of either a sec-
ond- or third-generation HC resulted in an increase in
UAE, although these increases were not significant after
adjustment compared with never-users. The rise in UAE





33.2%), whereas the fall in UAE























n = 117 P-value
Age (years) 39.1 (± 4.3) 37.4 (± 4.6)* 37.6 (± 4.6)* 36.5 (± 4.5)* <0.001
Body mass index (kg m−2) 25.0 (± 4.4) 24.3 (± 3.6) 24.7 (± 3.8) 24.2 (± 4.3) 0.34
Systolic blood pressure (mmHg) 114.0 (± 13.3) 114.8 (± 10.5) 117.7 (± 13.3)* 114.6 (± 12.7) 0.02
Diastolic blood pressure (mmHg) 67.4 (± 8.0) 67.8 (± 7.5) 69.1 (± 7.7) 68.1 (± 7.4) 0.17
Glucose (mmol l−1) 4.4 (± 1.0) 4.4 (± 0.6) 4.3 (± 0.7) 4.4 (± 0.6) 0.71
Cholesterol (mmol l−1) 5.1 (± 1.3) 5.0 (± 1.0) 5.0 (± 1.5) 5.0 (± 0.9) 0.88
Urinary albumin excretion (mg 24 h−1) 8.4 (3.9, 18.4) 8.3 (4.4, 15.4) 9.7 (4.1, 23.0) 8.9 (4.5, 17.9) 0.23
Estimated glomerular filtration rate
(ml min−1 1.73 m−2)
82.1 (± 11.9) 81.1 (± 13.2) 78.3 (± 11.4)* 81.7 (± 10.0) 0.01
Smoking (%) 46.8 52.1 52.7 53.8 0.48
History of myocardial infarction (%) 0.7 0.0 0.5 0.0 0.74
Use of lipid-lowering drugs (%) 0.3 2.7 1.6 1.7 0.29
Use of statins (%) 0.0 2.7 1.6 1.7 0.11
Use of antihypertensives (%) 5.9 4.1 5.5 3.4 0.73
Use of renin – angiotensin system inhibitors (%) 1.4 0.0 1.1 1.7 0.74
Use of antidiabetics (%) 0.3 0.0 0.0 0.0 0.73
Continuous variables are presented as mean and SD; categorical variables are presented as percentage; urinary albumin
excretion is presented as geometric mean and 95% confidence intervaI; P-value indicates whether mean or prevalence of a
certain variable differs between groups (using one-way ANOVA for mean and Pearson χ2 for percentage).*P-value < 0.05
indicates mean of a certain variable differs between this group compared with never-users using the Tukey test.
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second-generation HC (−16.9%) and both were signifi-
cant compared with never-users after adjusting for con-
founding factors. The changes in GFR among starters,
continuers or stoppers of HC, either a second or third
generation, were not significantly different compared
with never-users (Table 3).
Discussion
We found that the start of HC may induce a rise in SBP
and DBP with an, albeit, insignificant rise in UAE and
fall in GFR. Cessation of the use of HC was associated
with a statistically significant fall in SBP, DBP and
UAE, and a preservation of kidney function.
This study is the first to evaluate the effect of HC use
on BP and renal outcome in the general population dur-
ing long-term follow-up and also considers the effect of
the withdrawal of HC. Short-term studies have showed
that the administration of HC is associated with a rise
in BP [5–7]. Ribstein et al. [5] reported that both in
normotensive and hypertensive subjects, HC users had
a significantly higher BP compared with non-users.
Activation of the RAS is considered as an important
factor leading to the increase in BP, since estradiol
administration stimulates the hepatic synthesis of angio-
tensinogen [2, 25]. In another study, Lubianca et al. [8]
have reported a significant decrease in SBP and DBP in
women who stopped the use of contraceptives compared
with those who did not. Thus, our long-term observa-
tional data on BP confirm the findings of short-term
intervention studies.
Regarding the effects of HC on UAE, various short-
term studies and cross-sectional epidemiological studies
have shown an association of HC use and urinary albu-
min loss [3, 5, 10]. Our previous study, for example,
using data of the first screening of the PREVEND
cohort, showed that women receiving HC had a 90%
increased risk for microalbuminuria (UAE 30–300 mg
day−1) compared with non-users [10]. Ribstein et al. [5]
found a significant increase in 24-h UAE in normoten-
sive as well as hypertensive women using oral contra-
Table 2
Use of hormonal contraceptives in relation to blood pressure urinary albumin excretion and glomerular filtration rate
Type of
HC user N First screening Second screening P-value* % change P-value†
Systolic blood pressure (mmHg)
Never-users 286 114.0 (±13.3) 113.9 (±12.7) 0.838 +0.3 (±8.5) Reference
Starters 73 114.8 (±10.5) 117.7 (±12.3) 0.023 +2.8 (±9.1) 0.002
Continuers 183 117.7 (±13.3) 117.4 (±14.2) 0.664 −0.02 (±8.4) 0.162
Stoppers 117 114.6 (±12.7) 111.7 (±12.6) 0.001 −2.3 (±7.2) 0.041
Diastolic blood pressure (mmHg)
Never-users 286 67.4 (±8.0) 68.1 (±7.6) 0.035 +1.4 (±8.0) Reference
Starters 73 67.8 (±7.5) 70.0 (±7.1) 0.002 +3.6 (±8.5) 0.008
Continuers 183 69.1 (±7.7) 70.0 (±8.6) 0.041 +1.6 (±8.6) 0.152
Stoppers 117 68.1 (±7.4) 67.0 (±7.5) 0.020 −1.4 (±7.5) 0.015
Urinary albumin excretion (mg 24 h−1)
Never-users 286 8.4 (3.9, 18.4) 8.9 (4.0, 20.0) 0.081 +5.9 (−0.7/12.8) Reference
Starters 73 8.3 (4.4, 15.4) 9.5 (3.7, 23.9) 0.074 +14.2 (−1.0/31.9) 0.201
Continuers 183 9.7 (4.1, 23.0) 9.9 (4.1, 24.3) 0.580 +2.3 (−5.7/11.0) 0.809
Stoppers 117 8.9 (4.5, 17.9) 8.0 (4.3, 14.8) 0.021 −10.6 (−18.7/−1.8) 0.023
e-Glomerular filtration rate (ml min−1 1.73 m−2)
Never-users 286 82.1 (±11.9) 78.7 (±13.1) <0.001 −4.0 (±10.7) Reference
Starters 73 80.8 (±13.2) 75.0 (±13.2) <0.001 −6.3 (±13.0) 0.074
Continuers 183 78.3 (±11.4) 76.2 (±13.2) 0.002 −2.4 (±10.9) 0.409
Stoppers 117 81.7 (±10.0) 80.5 (±11.0) 0.167 −1.0 (±11.3) 0.036
Urinary albumin excretion (UAE) is presented in geometric mean and 95% confidence interval; % change systolic (SBP) and
diastolic blood pressure (DBP) and estimated (e-) glomerular filtration rate are presented as mean and SD; P-value* indicates
whether UAE, SBP, DBP and e-GFR differs between first and second screening (using paired sample t-test); P-value† associated
with dummy variable for group, adjusted for baseline age, SBP, DBP, cholesterol, glucose, UAE and body mass index (using
multivariate linear regression analysis); including the use of antihypertensives at baseline in the model did not change the result.
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ceptives when compared with non-users. Similar results
were observed in a recent study in a diabetic population
by Ahmed et al. [3], who reported that in this population
18% of contraceptive users developed macroalbumin-
uria (UAE >300 mg day−1) compared with 2% in non-
users (relative risk =8.90). Interestingly, in our study a
significant reduction in UAE was observed among
women that stopped the use of HC, suggesting a
reversible effect after discountinuation of HC. This fall
in albuminuria was seen in stoppers of second-
generation HC but not in those who stopped third-
generation HC.
It is of interest that our study is able describe age-
related changes in renal function over time. It is well
known that renal function will decrease with age. We
found that, compared with women who never used HC,
those who started to use HC tended to have a greater
decline in GFR over time, while those who stopped HC
had less decline in GFR. At first sight this seems to
conflict with data that showed that HC users have sim-
ilar [5] or a higher [3] GFR than non-users. This led
these authors to suggest that HC use may be associated
with glomerular hyperfiltration, thus also explaining the
risk of microalbuminuria. Our data suggest long-term
use of HC induces a fall in GFR. However, the reassur-
ing finding of our data is that these unfavourable effects
of HC are reversible after withdrawal, even after many
years.
We separately studied whether these renal effects of
HC were seen more in second- vs. third-generation OC.
Our data do not allow firm conclusions on this issue,
partly because there were only few women on third-
generation agents. If any conclusion can be drawn, there
may be a tendency for stopping HC use to result in an
improvement in BP, UAE and GFR in women using
second-generation HC, while there were no changes
observed in stoppers of third-generation HC. This sug-
gests that third-generation HC may be more deleterious
Table 3
Change in blood pressure, urinary albumin excretion and glomerular filtration rate according to different generation of hormonal 
contraceptives
Type of
HC user Second generation of HC Third generation of HC
N % change SBP P-value† N % change SBP P-value†
Never-users 286 +0.3 (±8.5) Reference 286 +0.3 (±8.4) Reference
Starters 45 +0.4 (±7.3) 0.379 17 +5.3 (±12.0) 0.004
Continuers 100 −0.7 (±7.6) 0.519 30 +0.7 (±7.1) 0.733
Stoppers 67 −2.5 (±7.2) 0.045 26 −0.2 (±7.9) 0.896
N % change DBP P-value† N % change DBP P-value†
Never-users 286 +1.4 (±8.0) Reference 286 +1.4 (±8.0) Reference
Starters 45 +2.1 (±7.8) 0.282 17 +6.1 (±10.2) 0.010
Continuers 100 +1.3 (±8.6) 0.171 30 +0.5 (±6.6) 0.437
Stoppers 67 −1.2 (±7.7) 0.093 26 +0.2 (±7.7) 0.658
N % change UAE P-value† N % change UAE P-value†
Never-users 286 +5.9 (−0.7/12.8) reference 286 +5.9 (−0.7/12.8) Reference
Starters 45 +14.3 (−7.1/40.5) 0.188 17 +19.6 (−6.2/52.6) 0.465
Continuers 100 −5.6 (−15.1/4.9) 0.663 30 +33.2 (6.4/66.6) 0.032
Stoppers 67 −16.9 (−28.0/−4.2) 0.011 26 +7.5 (−7.0/24.3) 0.788
N % change e-GFR P-value† N % change e-GFR P-value†
Never-users 286 −4.0 (±10.7) Reference 286 −4.0 (±10.7) Reference
Starters 45 −6.7 (±13.9) 0.052 17 −9.2 (±9.2) 0.058
Continuers 100 −1.0 (±11.4) 0.057 30 −4.8 (±10.0) 0.422
Stoppers 67 −1.4 (±10.0) 0.183 26 −1.3 (±14.5) 0.195
HC (hormonal contraceptives); urinary albumin excretion (UAE; mg 24 h−1) are presented in geometric mean and 95%
confidence interval; % change systolic and diastolic blood pressure (SBP and DBP; mmHg) and estimated glomerular filtration
rate (e-GFR; ml min−1 1.73 m−2) are presented in mean and SD. P-value† associated with dummy variable for group, adjusted
for baseline age, SBP, DBP, cholesterol, glucose, UAE, and body mass index (using multivariate linear regression analysis);
including the use of antihypertensives at baseline in the model did not change the result.
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than second-generation HC from a renal aspect. This
may be in agreement with the data that there is a rela-
tionship between HC use and inflammatory markers, in
particular in women taking third-generation agents. The
latter has been argued to contribute to an increased risk
of atherothrombotic [6] and peripheral arterial disease
[26]. A recent prospective, cross-over, randomized study
found no association between second- and third-
generation HC and inflammation markers such as the
concentration of serum C-reactive protein [27]. A recent
meta-analysis by Baillargeon et al. [28] reported an
increased risk of both cardiac and vascular events
among second- and third-generation OC users; however,
the risk in third-generation users seems less than in
second-generation users.
Several potential limitations of the present study
should be considered. First, we were able to analyse
only half of the women who had participated in the
previous screening, because approximately 20% of the
women withdrew consent and from participating women
only 60% had complete information on pharmacy data
for the entire study period. However, the baseline char-
acteristics of the women who were lost to follow-up did
not differ statistically significantly from those who
remained in the study, suggesting that loss to follow-up
was not an important source of bias. Second, this study
did not include women <28 years old and a high per-
centage of our population were current or past smokers
at baseline. Third, bias may have been introduced
through confounding by indication or contraindication
for HC use. This may apply particularly to women on
third-generation agents, since these preparations were
originally introduced to protect against myocardial inf-
arction due to their favourable effect on the lipid profile
[29]. The major strength of this study is that we were
able to provide long-term prospective follow-up with
monitoring of pharmacy records in a large sample of the
general population. Furthermore, its design enabled us
to compare the effect of HC in women who used HC at
first screening but stopped it afterwards, vs. subjects
who never used these agents, used them continuously,
or started their use.
In conclusion, the use of HC on women aged 28–
45 years is independently associated with a worsening
of BP, UAE and GFR, while stopping HC use
resulted in an improvement. With respect to the gen-
eration of HC, our data suggest that third-generation
might be more deleterious than second-generation
HC. These data suggest that long-term use of HC
may be deleterious from a cardiovascular and renal
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